CD86 and neoplasm: Furthermore, IHC analysis in the above mGSCs or GL261 tumor specimens showed that TNFRSF14 antibody treatment led to less CD206+ and more CD86+ TAMs infiltration (Fig. 6I, K and Figure S7G, H).